{"id":"W2024930123","doi":"10.1016/s0140-6736(14)61399-4","title":"PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial","year":2014,"lang":"en","type":"article","venue":"The Lancet","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":751,"is_retracted":false,"has_abstract":false,"ca_institutions":"Montreal Clinical Research Institute; Université de Montréal","funders":"Ipsen; Novo Nordisk; Otsuka America; Novartis; AbbVie; Genzyme; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Amgen; Pfizer; Bayer HealthCare; Meso Scale Diagnostics; Sanofi; Merck; Abbott Laboratories","keywords":"Evolocumab; Ezetimibe; Medicine; Placebo; PCSK9; Familial hypercholesterolemia; Cholesterol; Statin; Alirocumab; Internal medicine; Clinical trial; Dosing; Ldl cholesterol; Gastroenterology; Endocrinology; Lipoprotein; LDL receptor; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001397513,0.001956942,0.003381325,0.0004574191,0.0004224501,0.001198315,0.0009025279,0.002441536,0.005698921],"category_scores_gemma":[0.001520816,0.0008316133,0.002693672,0.0003655113,0.001177187,0.001017941,0.0003654714,0.002746347,0.001094362],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006466117,"about_ca_system_score_gemma":0.0005451514,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001215755,"about_ca_topic_score_gemma":0.002743533,"domain_scores_codex":[0.9995136,0.0002019912,0.00003842425,0.0001058426,0.00004021719,0.00009985178],"domain_scores_gemma":[0.9994791,0.0001576653,0.0001071829,0.0000467932,0.00003529173,0.0001739097],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9817633,0.001310118,0.0004178008,0.001036515,0.001623678,0.00007292916,0.00004246992,0.0001185571,0.001739501,0.00009898709,0.0007466367,0.01102958],"study_design_scores_gemma":[0.9773516,0.0187732,0.001697861,0.00006691426,0.001072088,0.00005222343,0.00002192841,0.0001657836,0.0002108423,0.00009211941,0.0004778302,0.00001754612],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9758338,0.01670961,0.0006676873,0.0008181557,0.001405694,0.001388789,0.0007359494,0.0002061264,0.002234192],"genre_scores_gemma":[0.9849212,0.006479123,0.001068575,0.001427218,0.0007652879,0.001227354,0.0007315766,0.00002700282,0.003352673],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005698921,"threshold_uncertainty_score":0.01906478,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0287132061087211,"score_gpt":0.2783745620263545,"score_spread":0.2496613559176334,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}